***Draft for Comments || Revised Guidelines on Good Manufacturing Practice (GMP) Clearance for Foreign Drug Manufacturers ***
All comments can be sent at oddgfroo@fda.gov.ph. Deadline of submission of comments shall be by 21 November 2021.
I. RATIONALE AND BACKGROUND
Consistent with State policy under Section 3 of RA 9711 “(a) protect and promote the right to health of the Filipino people; and (b) help establish and maintain an effective health research, responsive to the country’s health needs and problems, the State must enhance its regulatory capacity and strengthen its capability with regards to the inspection, licensing and monitoring of establishments, and the registration and monitoring of health products.
Read more:->https://bit.ly/3jsOLQb
Post from Food and Drug Administration Philippines
NSI Training and Consultancy Services, Inc. 